Asset profile
Elranatamab
Multispecific antibody
Evidence outlook
Accelerated approval: Multiple Myeloma (label: relapsed/refractory multiple myeloma after >= 4 prior lines of therapy)
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Elranatamab: this drug | Approved | Multispecific antibody | BCMA x CD3 | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Teclistamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| BCD-248 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| CM336 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| GR1803 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | ||
| REGN5459 | Phase 1/2 | Multispecific antibody | BCMA x CD3 | ||
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(34 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (10)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
July 2027 (2)
August 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (4)
August 2028 (1)
What to watch
September 2028 (1)
What to watch
2029 (7)
January 2029 (1)
What to watch
April 2029 (1)
August 2029 (1)
What to watch
October 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (4)
September 2030 (1)
What to watch
October 2030 (1)
What to watch
November 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (1)
June 2031 (1)
What to watch
2032 (3)
February 2032 (1)
What to watch
June 2032 (1)
What to watch
November 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.